



Opicapone

Catalog No: tcsc3109



Ava	ila	bl	e	S	ize	25
\neg						

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

923287-50-7

Formula:

 $C_{15}^{}H_{10}^{}Cl_{2}^{}N_{4}^{}O_{6}^{}$

Pathway:

Neuronal Signaling; Metabolic Enzyme/Protease

Target:

COMT;COMT

Purity / Grade:

>98%

Solubility:

DMSO: 1.25 mg/mL (3.03 mM; Need ultrasonic and warming)

Alternative Names:

BIA 9-1067

Observed Molecular Weight:

413.17

Product Description





Opicapone is an available catechol-O-methyltransferase (**COMT**) inhibitor. Opicapone decreases the ATP content of the cells with IC values of 98 μ M.

IC50 & Target: COMT^[1]

In Vitro: Opicapone has a prolonged inhibitory effect on peripheral COMT, which extends the bioavailability of levodopa, without inducing toxicity. Opicapone decreases the ATP content of the cells with IC₅₀ values of 98 μ M. Incubation of human primary hepatocytes for 24 h with increasing concentrations of Tolcapone, entacapone or Opicapone resulted in a concentration-dependent decrease in the mitochondrial membrane potential of the cells, evaluated by the ratio JC-1 aggregates over JC-1 monomer (ratio $\lambda_{\rm ex}$ 544 $\lambda_{\rm em}$ 590 over $\lambda_{\rm ex}$ 485 $\lambda_{\rm em}$ 538). Opicapone decreases the mitochondrial membrane potential of the cells with IC₅₀ of 181 μ M^[1].

In Vivo: Opicapone inhibits rat peripheral COMT with ED₅₀ values below 1.4 mg/kg up to 6 h post-administration. The effect is sustained over the first 8 h and by 24 h COMT had not returned to control values. A single administration of Opicapone resulted in increased and sustained plasma levodopa levels with a concomitant reduction in 3-O-methyldopa from 2 h up to 24 h post-administration, while Tolcapone produced significant effects only at 2 h post-administration. The effects of Opicapone on brain catecholamines after levodopa administration are sustained up to 24 h post-administration. Opicapone is also the least potent compound in decreasing both the mitochondrial membrane potential and the ATP content in human primary hepatocytes after a 24 h incubation period^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!